MPN Watch

Dossier web review 2026-04 (recent)

NCCN Updates Guidance on Interferon in Essential Thrombocythemia

Key claim: NCCN has elevated interferon to a Category 1 recommendation for essential thrombocythemia management, signaling that clinical evidence supporting this treatment approach has sufficiently matured.

Abstract

The MPN Research Foundation highlights NCCN’s Category 1 designation for interferon in ET management, described as a significant regulatory signal that data have matured to support this treatment approach for clinicians, patients, and payers.

Why this matters

Pending synthesis.

Source

Link

Briefing card

NCCN Updates Guidance on Interferon in Essential Thrombocythemia
Stage: review · web · 2026-04 (recent)

NCCN has elevated interferon to a Category 1 recommendation for essential thrombocythemia management, signaling that clinical evidence supporting this treatment approach has sufficiently matured.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://mpnresearchfoundation.org/

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Subscribe: calendar of upcoming dates · deadlines feed · all new records · Help

build build 612 · 69ce4cf-dirty · 2026-11-11